Colorectal cancer is the 3rd most common malignant neoplasm in the West. About 50% of patients develop liver metastases throughout the course of the disease. Those are res ponsible for at least twothirds of deaths. Advances in surgical techniques and improve ment in chemotherapy regimens have allowed offering treatment with curative intent to an increasing number of patients. This article reviews recent advances in the treatment of liver metastases, including strategies to increase resection (e.g., portal vein emboliza tion, radiofrequency ablation, twostage hepatectomy, conversion therapy and reverse treatment strategy) and hepatectomy in the presence of extrahepatic disease. Finally, the results of surgical treatment of liver metastases at the Hospital A.C. Camargo are briefly shown.
. The present article reviews the recent advances in the treatment of liver metastases, including strategies to increase resection and hepatectomies in the presence of extrahepatic disease. Finally, we briefly show the results of the surgical treatment of liver metastases in Hospital A.C. Camargo.
reSectabIlIty crIterIa
The capacity to remove all liver metastases with free margins and preserve a future remnant liver (FRL) of at least 20% of the total liver volume (TLV) in patients with a healthy liver, in the absence of unresectable extrahepatic disease, defines most cases regarding liver resectability. Moreover, it is nec essary to guarantee adequate arterial and portal inflow, as well as biliary drainage and venous return (outflow). Some patients might need a FRL volume > 20%.
Patients that have been submitted to many chemother apy cycles (intensive chemotherapy) need FRL of at least 30%, whereas for patients with chronic hepatopathy one can estimate 40%. There is still a great deal of controversy regarding what is considered intensive chemotherapy. In Hospital A. C. Camargo, that is considered as more than six cycles of the usual regimen carried out currently, such as FOLFOX (5Fluorouracil and oxaliplatin), FOLFIRI (5Fluorouracil and irinotecan) or FOLFOXIRI (5Fluoro uracil, oxaliplatin and irinotecan).
In patients candidate to extensive resections, it is nec essary to calculate with higher accuracy the FRL volume. For that purpose, it is necessary to perform liver volum etry. The direct measurement of the FRL is performed by computed tomography (CT). Among the existing formu las, we used the one described by Vauthey et al. to calculate the standardized total liver volume 1213 ( Figure 1 ). As for the margin, differently from what was believed in the past, a margin of at least 1 cm is not mandatory. Busquets et al. 14 in a multicentric study with 557 patients, compared the resection margins from 1 mm to 1 cm and observed that there was no significant difference in global and freeofdisease survival. Therefore, the main objective is to achieve free margins, even though the goal is a 1cm margin 14 . preoperaTive evaluaTion and sTaging examinaTion Initially, the sequelae of previous treatments (for in stance, previous hepatectomy and chemotherapy) must be considered as well as patients' comorbidities (obesity, diabetes mellitus, alcohol consumption, liver cirrhosis). The morbidity associated with liver steatosis, very often a consequence of the systemic treatment, is a controversial issue, as although there is a histological liver lesion, its influence on mortality remains controversial 15 . The main examination to be carried out for the stag ing is the CT with a protocol for liver, where thinsection CT images are acquired (preferably in equipment with multidetectors) in four phases: precontrast, arterial, portal and equilibrium or late phase. It is considered the goldstandard by most specialized centers, as it allows the accurate assessment of resectability, the number of nodules and their association with liver structures and adjacent organs, in addition to performing the liver volu metry.
Other examinations can also be effectively per formed, especially the magnetic resonance (MR), which allows the acquisition of images that are equivalent to the tomography in terms of quality. Some believe that at this time of preoperative chemotherapy and obesity, the MR can be very important, due to the higher capacity of dif ferentiating areas of steatosis from secondary nodules, which has yet to be definitively demonstrated.
The colonoscopy must be always used to rule out the possibility of primary tumor recidivism. Chest images by xrays or CT are also mandatory to assess the presence of lung metastases.
The positron emission tomography (PET)CT is the new tool for the staging of these patients, but there is no consensus on its use to date. Fernandez et al. 16 evaluated 100 patients with liver metastases of colorectal origin that were submitted to PETCT in the preoperative period and concluded that there are survival advantages when the 18FFluorodeoxyglucose (FDG) PET/CT is used, due to better patient selection for surgery, with a 5year survival of 58% being observed in this group of patients; however, the great criticism faced by this study is not comparing PETCT with the currently available highdefinition to mographic images. One must be aware of falsenegative results after the chemotherapy. Thus, even when there is no uptake of a nodule visualized before the chemo therapy, the indication for resection is maintained, as the decreased sensitivity of PETCT in detecting metastases postchemotherapy is wellknown 17 , mainly before two weeks after its completion.
The PETCT can also predict the response to chemo therapy when 18FFU is used instead of 18FFDG 18 . One of the most important questions regarding the restaging postchemotherapy is the discrepancy be tween imaging study results and surgical findings 19, 20 . Angliviel et al. 20 showed that there is more than 50% of result discrepancy in CT findings postchemotherapy at the restaging when compared with the surgical findings. Carnaghi et al. 19 pointed out that both PETCT and CT have limited sensitivity (60%) for restaging of CRLM postchemotherapy, especially for lesions < 1 cm.
Benoist et al. 21 evaluated 66 patients that had com plete response at the imaging examinations after "neo adjuvant" chemotherapy and were submitted to surgical exploration and systematic clinical followup. Of these, 32 had lesions identified at the surgery and 23 were iden tified at the clinical followup in the same sites of the pre vious lesion. The conclusion is that 83% of the patients that had a complete response at the imaging examina tions have macro or microscopic residual disease or early recidivism. From our point of view, this information is of utmost importance for the indication of surgical explora tion and resection of previously compromised areas, even in patients in whom complete radiological response was observed and for whom a curative treatment is intended.
surgiCal TreaTmenT
The surgical procedure must be initiated with the sys tematic exploration of the abdominal cavity, with spe cial attention when assessing the presence of extra hepatic disease. Colon, peritoneum, retroperitoneal lymph nodes, celiac trunk and hepatic hilum are evalu ated and biopsies and microscopic examination of fro zen samples are carried out in all suspected sites.
All assessment modalities are important during liver evaluation. The presence of nodules, postchemothera py scars, retractions or areas suggestive of fibrosis must be observed. At palpation, the presence of hardened, round, firm, or fibroelastic areas that can be superfi cial, easily palpable or deep can be noticed. These must be assessed carefully, as the presence of the liver paren chyma between the tumor and the examiner's hand can make the evaluation difficult. The examination must be carried out by surgeon by sliding the hands over the entire liver surface and it must always be bimanual, in creasing the sensitivity to identify deep lesions, espe cially in the left lobe.
The intraoperative ultrasonography is currently an essential tool for staging and surgical planning and therefore, a mandatory examination in any liver sur gery. It can identify 20% to 30% of the nodules that were not detected at the conventional examinations. In our country, Cohen MP et al. 22 demonstrated that the in traoperative ultrasonography in surgeries performed to resect liver metastases changes the surgical strategy in 25.7% of the cases and is extremely useful in identifying lesions < 1 cm.
The type of resection must guided by the number and location of lesions and by the need to attain tumor free margins. The anatomic resections, that is, exeresis of liver segments or lobes, respecting the regions de limited by venous and arterial vascularization, in addi tion to the biliary drainage, are preferable, as they allow lower blood loss and carry a lower risk of compromised margins. However, there is no difference in survival re garding the nonanatomical resections, as long as the margins are free 23, 24 . The types of resection are: segmen tectomies, bisegmentectomies, central hepatectomies, lobectomies, trisegmentectomies, enucleations and combinations of these forms. Resections that are con comitant to the primary tumor are safe and feasible, as long as they are carried out by an experienced tem and follow the oncologic principles.
sTraTegies To inCrease reseCTabiliTy As previously described, resectability is currently de fined by a new paradigm, where the possibility of re section of liver lesions must be considered, as well as the complete resection of extrahepatic lesions and the quality (inflowoutflow) and quantity of remnant liver after the surgery and not exclusively by the tumor clini copathological factors. Therefore, previously used cri teria, such as number of nodules, size of lesions, bilat eralism and presence of extrahepatic disease (as long as resectable) must be considered prognostic factors and not a contraindication for resection. Based on these principles, strategies are defined, which will allow the resection of extensive disease in several circumstances where they would previously be considered unresectable. Still, there are cases in which complete resection with FRL volume cannot be attained with the usual techniques. In this situation, other tech niques are employed to increase resectability.
Portal veIn embolIzatIon
In general, 20% of the normal FRL is considered safe after an extensive resection. However, the sectioning volume for FRL in patients with livers presenting steatosis, steato hepatitis (30% RLV) or cirrhosis (> 40%) must be higher. In general, the right lobe represents twothirds of the liver volume and the left only onethird. Frequently, patients with multiple liver lesions are submitted to right hepatectomy ex tended to segment IV (or right trisegmentectomy).
On average, these surgeries remove around 84% of the liver volume in the absence of compensatory hypertrophy of the remnant liver 25 . However, a high degree of indi vidual variation can be observed in the volumes of liver segments and lobes. To prevent surgeries in patients with FRL lower than the desired volume, the portal vein embo lization must be carried out to induce contralateral lobe hypertrophy 25 . The idea came from the observation that when there is invasion of a portal vein branch by the tumor, there is hypertrophy of the contralateral lobe. Technically it is performed through catheterization by radioscopy of the lobe or segmental vein, followed by vessel embolization by embolic material (coils, thrombin, cyanoacrylate, mi crospheres, etc). It is a relatively safe procedure; its rate of complications varies from 5% to 8%. Then expected vol ume growth of the FRL is of 8% to 16% 2628.
The portal vein embolization is more frequently used as part of the multimodal treatment regimens, which in clude preoperative chemotherapy and hepatectomy, as most part of these patients already presents with more than one factor of poor prognosis, such as multiple lesions, bilobar lesions, compromised lymph nodes at the primary and extrahepatic metastases.
Some authors evaluated whether the use of CT before or after the portal embolization could impair liver hyper trophy; however, the results showed no impairment in liver hypertrophy when volume increase is desired 29, 30 .
two-Stage hePatectomy
In extreme situations, in which there are multiple metas tases in both hepatic lobes, twostage resections can be the best therapeutic option and the only chance of cure, pre serving an adequate volume of FRL.
The initial results had a high rate of liver failure and postoperative mortality > 10% 31 , very different from what is currently observed with the routine use portal vein em bolization in specialized centers.
The recommendation is that at the first intervention, the removal of the liver metastasis be carried out in the liver parenchyma that one wishes to preserve (FRL), to prevent the excessive growth of metastases after the portal flow deviation by embolization. It is usually a parenchyma sparing resection carried out in the lobe or segments that exhibit less disease damage (usually the left lobe) attaining tumorfree margins, and allowing the preservation of most of the lobe or segments in question. There is a 4to6 week interval to surgery and volumetry control is always per formed before and after this period, to ensure that there is FRL with an adequate volume.
At the second stage of the procedure, a more extensive resection is performed, most often from the right lobe, which extends to the IV segment. It is seldom necessary to perform left portal vein embolization for right lobe hyper trophy, as the volume of the latter is hardly ever lower than the desired volume. As it is a complex procedure, it must be performed only in curative situations.
In several situations, CT is indicated during the time between the embolization and surgery, without the use of monoclonal antibody (Bevacizumab), when it is being used in the CT regimen. The objective is to prevent tumor growth during the period when waiting for the second phase of the surgery.
radIofrequency
Another alternative to the twostage surgery is the asso ciation of radiofrequency (RF) ablation with liver resec tion, which in some situations can expand the number of patients eligible for surgery. However, the RF has a higher risk of recidivism in comparison with the resection, main ly in lesions > 3 cm. It use must be restricted to cases in which the resection is not possible due to lack of adequate FRL volume 7 .
converSIon theraPy
Many patients have such extensive liver disease at diag nosis that they cannot be candidates to liver resection through any of the strategies mentioned before. However, there are cases in which the reduction of hepatic lesions through CT can enable the surgical treatment, transform ing an initially unresectable disease into a resectable one. When the CT is used for that purpose, it is called conver sion chemotherapy. The conversion CT consists of administration of thera peutic regimens with a high rate of response, aiming at the decrease in tumor volume to allow the resection of metas tases, while obtaining an adequate liver volume.
The main therapeutic options are FOLFOX or FOL FIRI, or a combination of both (FOLFOXIRI), with re sponse rates of 4866% 3235 , 3962%
3638 and 5671,4%
39,40 , respectively. According to some authors, there is a "con version" in around 10% to 20% of individuals initially con sidered to unresectable 9 , with survival rates similar to that observed in patients that are initially resectable 41 . Higher response rates can be obtained by adding targettherapy with cetuximab or bevacizumab.
CT duration must be only the necessary time for con version to occur, with no predetermined number of cycles. The intention is to submit the patient to surgery as soon as the lesions are resectable, preventing unnecessary liver toxicity that result from CT excess and also an eventual progression of the disease after a long period of treatment.
Thus, the patients must be followed together with the surgeon, through control image assessment every two months, aiming at detecting lesion response and identify ing, as soon as possible, the moment when the metastases become resectable. If there is no adequate radiological re sponse, a new CT scheme can be attempted, always aiming at conversion.
extrahePatIc dISeaSe
Traditionally, the presence of extrahepatic metastases of colorectal origin was considered an absolute contraindi cation for hepatectomy 42 . As a consequence of safer sur gical procedures and the evolution of the effectiveness of CT schemes, hepatic resections started to be performed in association with extrahepatic metastasis resection, for selected groups of patients. The main sites of extrahepatic disease to be considered are: portal lymph nodes, perito neum and lungs.
The metastases for portal lymph nodes in the context of CRLM result from the lymphatic drainage of the liver and thus, represent the localregional dissemination of liver metastases 43 . Patients with macroscopic metastases for por tal lymph nodes have an unfavorable evolution, with little chance of fiveyear survival 44, 45 . However, it is possible to select patients with a better prognosis based on the loca tion of the affected lymph nodes. Jaeck et al. 46 demonstrated that whereas patients with lymph node metastases along the common hepatic artery and celiac trunk have 0% 1year survival, those with lymph node metastases located in the hepatoduodenal ligament had a 38% 3year survival. These findings were confirmed by Adam et al. 47 , who showed a 5year survival of 25% in the analysis of 47 patients with perihepatic lymph node metastases in the hepatoduode nal ligament, whereas there were no survivors among those with metastases in the celiac or paraaortic trunk.
Therefore, only patients with hepatoduodenal ligament lymph node metastasis must be considered for liver resec tion. Those with retroperitoneal lymph node disease must receive palliative treatment.
The lungs, together with the liver, are the most com mon sites of metastases in colorectal tumors. Several stud ies have demonstrated that the resection of the lung dis ease can lead to longterm survival 48 . However, little has been studied on the presence of synchronic lung and liver metastases. Six studies addressed this question, showing that although it is often necessary to perform new resec tions per early recidivism, the global 5year survival var ies from 2774% 49 . The main factors that seem to influence prognosis are: number of pulmonary lesions, number of hepatic lesions and the synchronic versus metachronic presentation.
Peritoneal carcinomatosis occurs in 1325% of pa tients with colorectal tumors. If treated only with sys temic CT, this condition leads to death in less than one year, with a median survival ranging from 5.2 to 6.9 months 50 . However, similarly to hepatic metastases, it is believed that it does not always represent disseminated systemic disease, but a localregional form of dissemi nation (transmural deposit of tumor cells), which can be treated by peritonectomy and hyperthermic intra peritoneal chemotherapy (HIPEC) 51 . Thus, patients with restricted peritoneal disease can benefit from this treat ment 52 . Two studies specifically addressed the association between peritoneal carcinomatosis and liver metastases. Carmignani et al. 53 evaluated 27 patients with peritoneal carcinomatosis, of which 16 had liver metastases as the only additional site of the disease and 4 other had liver and lung metastases. The procedures aiming at complete cytoreduction had a morbidity of 14.8%, with no deaths and a median survival of 15.2%. Elias et al. reported on the treatment of 27 patients with CRLM and synchronic peritoneal carcinomatosis, of which 14 patients had car cinomatosis detected preoperatively and 13, intraopera tively 54 . There was a postoperative death (4%) on 14 th day due to undiagnosed peritonitis and the morbidity was 58%. With a median followup of 6.1 years, the global 5year survival was 26.5%, with seven patients being diseasefree; as for the cases of recidivism, only three had been located in the peritoneum. The only prognos tic factor with statistical significance was the number of liver nodules > 2. However, these findings still need to be corroborated by other randomized studies with larger samples. Thus, wellselected patients, as long as they are submitted to treatment in specialized centers, can un dergo the simultaneous treatment of liver metastases and peritoneal carcinomatosis.
reverSe treatment Strategy
Patients with synchronic liver metastases are classically submitted to primary tumor resection, followed by long CT periods and subsequently, if there is no disease pro gression during this period, they are referred to liver resection 55, 56 . However, patients with advanced liver dis ease can have metastasis progression during the primary tumor treatment, making the lesions unresectable. This problem becomes especially important in patients with rectal tumors (who often necessary need to undergo neoadjuvant RT, in which the concomitant CT has only a radiosensitizing function) and in those with surgical complications caused by the primary tumor treatment.
One strategy to attenuate this problem is to perform the liver resection together with the colorectal tumor re section. However, few patients are eligible for this proce dure and there are considerable limitations for extensive hepatectomies 57, 58 .
An attempt to overcome the problem has been the use of a new treatment strategy, called the reverse treatment strategy, where there is an inversion of the classic treat ment sequence 59, 60 . Hence, liver metastases -the main determinants for the definition of the treatment curative characteristic -are treated before the primary tumor. Patients with asymp tomatic colorectal tumor with large, but resectable liver metastases or patients with initially unresectable metasta ses that achieved conversion after chemotherapy are can didates to this type of treatment.
In our service, we recommend starting these patients' management with chemotherapy, aiming at the immediate treatment of both the liver metastases and the micrometa static systemic disease. The main concerns regarding this approach are the possibility of complications related to the primary tumor (pain, bleeding or obstruction) or the pro gression of liver metastases during the CT period. How ever, the first is a rare event, not different from the rates of complications or bridle obstructions in patients submitted to surgery 61, 62 , whereas the latter represents such a poor prognosis that these patients would hardly have benefited from any initial surgical treatment 63 .
treatment outcomeS
Even considering the increase in surgical indications for larger tumors, multiple nodules, synchronous bilobar lesions and extrahepatic disease, one can observe an in crease in survival throughout the last decades, going in a period of five years from 30% in the oldest series to more than 50% in the current ones (Table 1) . A published analysis of 70 patients submitted to sur gery in our institution between January 1999 and June 2005 showed a fiveyearsurvival of 51% 64 . A more recent reassessment of our series, taking into account 142 surger ies in 121 patients in recent years, showed a global survival of 66.2% in five years and 54.9% in seven years (data not published).
concluSIon
The perfecting of surgical techniques together with safer procedures, as well as the improvement in chemotherapy regimens have allowed doctors to offer patients with liver metastasis the possibility of curative treatment or long term survival. Factors that were previously considered contraindications for the surgery, such as number of me tastases, synchronous metastases and even the presence of extrahepatic disease, must be considered only as prognos tic factors and must not prevent the patient from having the opportunity of being treated.
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